Healthcare Recap: Centene and Molina ROCKET Higher

Shares of both Centene (NYSE:CNC) and Molina (NYSE:MOH) take OFF following Ohio’s awarding them Medicaid contracts for 2013. An earlier decision had dropped them, along with Aetna (NYSE:AET), from the state’s list of Medicaid plans, so Friday’s news is significant for both firms, which have large footprints there.

No one can call GlaxoSmithKline (NYSE:GSK) a quitter, as the firm re-extends its $2.6 billion offer to acquire Human Genome Sciences (NASDAQ:HGSI) until the end of June. As before, HGSI answers back that the $13 per share bid is “inadequate and does not reflect the value inherent” in the company.

Novo Nordisk (NYSE:NVO) shares wilt subsequent to its hitting one of the FDA’s ‘third rails’; the agency has extended its regulatory evaluation for the firm’s ultra-long-acting insulins degludec and insulin degludec/insulin by three months. The meds are part of the treatment of type 1 and type 2 diabetes.